Non-Muscle Invasive Bladder Cancer
Non-muscle-invasive bladder cancer (NMIBC) means the cancer has not invaded the detrusor muscle of the bladder. It includes papillary Ta tumours, T1 tumours that invade the lamina propria, and flat high-grade carcinoma in situ (CIS). NMIBC accounts for a large proportion of newly diagnosed bladder cancers, but it is not one low-risk category. A small solitary low-grade Ta tumour may need TURBT and surveillance, while high-grade T1 with CIS can carry a substantial risk of progression and may require BCG or even early radical cystectomy. Risk stratification after a high-quality TURBT is therefore the central step.
What do Ta, T1 and CIS mean?
| Stage | Where the cancer is | Typical significance |
|---|---|---|
| Ta | Papillary tumour confined to urothelium | Often low grade; recurrence can be common but progression risk is usually low when other features are favourable. |
| T1 | Invades lamina propria but not detrusor muscle | Higher risk, particularly when high grade; repeat TURBT is commonly required. |
| CIS | Flat high-grade tumour confined to urothelial layer | High-risk biology despite being non-muscle-invasive; often treated with BCG. |
Why risk stratification matters
Treatment intensity is based on more than stage. Important factors include grade, tumour size, number, recurrence rate, presence of CIS, depth of T1 invasion, histological variants, lymphovascular invasion and response to previous BCG. Current EAU guidance uses risk groups to estimate progression and guide intravesical therapy versus cystectomy discussion.
Low-risk NMIBC
A small solitary primary low-grade Ta tumour is often treated with complete TURBT plus a single immediate intravesical chemotherapy instillation when there is no concern for perforation or significant bleeding. Follow-up cystoscopy is still required because recurrence can occur.
Intermediate-risk NMIBC
This group is heterogeneous and may include recurrent, multiple or larger low-grade tumours without high-risk features. Options include a course of intravesical chemotherapy or BCG. The number and timing of instillations are tailored to recurrence risk, prior treatment and tolerability.
High-risk and very-high-risk NMIBC
High-grade Ta, high-grade T1 and CIS generally require more intensive treatment. BCG induction followed by maintenance is a standard bladder-preserving approach when appropriate. Very-high-risk features should prompt an early discussion of radical cystectomy because waiting for muscle invasion can reduce the chance of cure.
What is BCG-unresponsive disease?
BCG-unresponsive describes specific high-grade recurrences that occur despite an adequate BCG course and are unlikely to benefit from simply giving more of the same BCG. Radical cystectomy is the oncologically preferred standard for fit patients in many such situations. For patients who are unfit or decline cystectomy, alternative intravesical or systemic bladder-preserving treatments and clinical trials may be considered.
Why repeat TURBT may be needed
High-grade T1 disease has a meaningful risk of residual tumour or understaging after the first resection. A repeat TURBT can confirm that no muscle-invasive cancer was missed and improve local clearance before BCG. It is also indicated after an incomplete initial resection and in other situations where staging quality is inadequate.
Follow-up
Cystoscopy is the backbone of surveillance. Frequency depends on risk: high-risk patients require closer and longer follow-up than low-risk patients. Cytology and upper-tract imaging are added in selected high-risk plans. Recurrence is common enough that a long-term follow-up plan should be given in writing.
When should cystectomy be discussed?
- Very-high-risk NMIBC where progression risk is substantial.
- BCG-unresponsive high-grade disease in a fit patient.
- Persistent high-grade T1 after adequate repeat resection.
- Certain aggressive variant histologies or adverse pathological features.
- Recurrent high-grade disease despite appropriate intravesical therapy.
Risk group is more useful than the label NMIBC alone
| Risk pattern | Typical management direction |
|---|---|
| Low risk | Complete TURBT; often a single immediate intravesical chemotherapy instillation and less intensive surveillance. |
| Intermediate risk | Intravesical chemotherapy or BCG chosen according to recurrence/progression risk and treatment tolerance. |
| High risk | BCG with maintenance is commonly used; early radical cystectomy should also be discussed in appropriate patients. |
| Very high risk / BCG-unresponsive high-grade disease | Cystectomy becomes a major curative option; bladder-preserving alternatives require careful selection and counselling. |
The risk group can change at recurrence because stage, grade, tumour number, size, CIS and previous response to treatment can change. A patient should therefore know the risk category after each important TURBT rather than assuming the original label remains permanent.
Why repeat TURBT can change the treatment plan
A second TURBT is not simply “doing the same operation again.” It can remove residual tumour, improve staging and determine whether the first specimen underestimated invasion. It is particularly important in selected high-grade T1 disease, incomplete initial resection and situations where adequate detrusor muscle was not obtained.
If repeat resection still shows high-grade T1 disease, especially with additional adverse features, the threshold for discussing early radical cystectomy becomes lower. The purpose is to avoid discovering muscle invasion only after the window for the best curative treatment has narrowed.
Carcinoma in situ behaves differently from a papillary tumour
CIS is a flat high-grade lesion that may be difficult to see and can produce urinary urgency or burning that resembles infection. It has meaningful progression risk and is usually treated with BCG when bladder preservation is appropriate. Because it can be multifocal, urine cytology and careful cystoscopic surveillance are particularly relevant.
When to seek urgent medical care
Seek urgent care for clot retention or inability to pass urine, heavy persistent bleeding, high fever or rigors after TURBT/BCG, severe worsening pelvic/flank pain, fainting or rapidly worsening illness. Most cystoscopy or pathology findings can be reviewed in clinic, but high-grade recurrence should not be left until a routine distant appointment.
Consultation checklist
- All TURBT pathology reports.
- Stage, grade and whether detrusor muscle was present.
- Presence of CIS and variant histology.
- BCG or intravesical chemotherapy dates and number of instillations.
- Cystoscopy and urine cytology history.
- Upper-tract imaging.
- Kidney function and overall fitness if cystectomy may be considered.
FAQs
Is NMIBC the same as “superficial bladder cancer”?
The older term “superficial” can be misleading because T1 and CIS may be biologically dangerous. NMIBC is the preferred term.
Can NMIBC become muscle-invasive?
Yes. Risk is low for favourable low-grade Ta but substantially higher for high-grade T1 and CIS.
Does every NMIBC patient need BCG?
No. Low-risk tumours often do not. BCG is mainly used for selected intermediate-risk and high-risk disease.
Why is cystoscopy needed even after BCG?
BCG reduces recurrence and progression risk but does not guarantee eradication. Surveillance detects persistent or recurrent disease.
Can recurrent low-grade tumours be managed without repeated major surgery?
In selected patients, office fulguration, active surveillance or intravesical treatment may reduce treatment burden, but suitability depends on tumour size, number, history and certainty that disease remains low grade.
Does NMIBC mean the cancer is harmless?
No. Low-risk NMIBC is usually unlikely to progress, but high-grade T1 disease and carcinoma in situ can be biologically aggressive even though they have not yet invaded bladder muscle.
Related reading
- TURBT Surgery Explained
- Low-Grade vs High-Grade Bladder Cancer
- BCG Therapy for Bladder Cancer
- Intravesical Chemotherapy for Bladder Cancer
- Bladder Cancer Recurrence
- Follow-Up Cystoscopy After Bladder Cancer
- Radical Cystectomy Explained
- Seminoma vs Non-Seminoma
- Urologist in Latur
References
- European Association of Urology (EAU). EAU Guidelines on Non-Muscle-Invasive Bladder Cancer. 2026 edition https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer
- National Cancer Institute. Bladder Cancer Treatment (PDQ®)–Patient Version https://www.cancer.gov/types/bladder/patient/bladder-treatment-pdq
- American Urological Association/SUO. Non-Muscle Invasive Bladder Cancer Guideline (2016; amended 2024) https://www.auanet.org/guidelines-and-quality/guidelines/bladder-cancer-non-muscle-invasive-guideline